Welcome to our dedicated page for Azitra news (Ticker: AZTR), a resource for investors and traders seeking the latest updates and insights on Azitra stock.
Azitra Inc. develops clinical-stage precision dermatology therapies built around engineered proteins and topical live biotherapeutic products. Its pipeline includes ATR-12, an engineered S. epidermidis program for Netherton syndrome; ATR-04, an engineered S. epidermidis candidate for EGFR inhibitor-associated rash; and ATR-01, a program targeting ichthyosis vulgaris through delivery of recombinant human filaggrin.
Azitra news commonly covers patent protection, preclinical and clinical program updates, scientific presentations, business results, financing activity, shareholder meeting matters, and NYSE American listing-compliance notices. Company updates also reference its microbial discovery platform, artificial intelligence and machine-learning screening tools, and the use of genetically engineered bacteria and proteins for dermatology applications.
Azitra (NYSE: AZTR) priced a private placement providing gross proceeds of up to $31.4 million, including initial gross proceeds of $10.5 million and up to an additional $20.9 million upon potential cash exercise of warrants.
The financing issues 10,470 Series A preferred shares, Series B and C warrants exercisable at $0.123 per share, and supports new protein and peptide R&D for cosmetic and cosmeceutical commercialization.
Azitra (NYSE: AZTR) received a NYSE American notice of non-compliance under Sections 1003(a)(ii) and 1003(a)(iii) for minimum stockholders' equity requirements and has until April 1, 2027 to regain compliance. The Exchange accepted Azitra's previously submitted Plan on December 16, 2025.
The company noted an audit opinion including a going concern paragraph in its Form 10-K for the year ended December 31, 2025. Azitra will remain listed during the plan period while exploring multiple funding avenues.
Azitra (NYSE: AZTR) announced cancellation of its special meeting of stockholders that had been originally scheduled for February 6, 2026 and adjourned to March 6, 2026 due to a lack of quorum.
The company is a clinical‑stage biopharmaceutical developer of engineered S. epidermidis programs, including ATR-12 (Phase 1b for Netherton syndrome) and ATR-04 (FDA Fast Track for EGFRi associated rash; open IND). Azitra’s platform includes ~1,500 bacterial strains and AI/ML screening tools.
Azitra (NYSE American: AZTR) reported full-year 2025 results and clinical progress. Key clinical advances include dosing the first patient in the Phase 1/2 ATR-04 trial (EGFRi-associated rash), Fast Track designation for ATR-04, promising Phase 1b safety data for ATR-12 in Netherton syndrome, and positive preclinical ATR-01 data.
Financials: R&D $4.8M, G&A $6.2M, net loss $11.0M, and cash & equivalents $2.1M; completed $8.5M financing activity in 2025.
Azitra (NYSE:AZTR) added The University of Texas MD Anderson Cancer Center as a clinical site for its Phase 1/2 study of topical ATR-04 (ATR04-484) for EGFR inhibitor-associated skin rash.
The multicenter, randomized, double-blind study (NCT06830863) is enrolling Cohort 1 (anticipated eight patients). ATR-04 has FDA Fast Track designation and an open IND.
Azitra (NYSE American: AZTR) will present at the BIO Investment & Growth Summit in Miami Beach on March 2-3, 2026, with a formal presentation on March 2 at 2:15 PM ET.
Management will highlight pipeline updates for ATR-12 (Phase 1b), ATR-04 (Phase 1/2) and ATR-01 (IND-enabling), and hold one-on-one investor meetings.
Azitra (NYSE American: AZTR) adjourned its virtual Special Meeting held Feb 6, 2026, to March 6, 2026 at 11:00 a.m. ET because a quorum was not present. Proxies then represented approximately 13% of outstanding voting shares; a quorum requires 33 1/3%.
The Reconvened Special Meeting will consider two proposals: approval to issue more than 19.99% of outstanding common stock underlying warrants under a Nov 24, 2025 Purchase Agreement with Alumni Capital LP, and a potential adjournment to solicit additional proxies.
Azitra (NYSE American: AZTR) will present at Biotech Showcase in San Francisco on January 13, 2026 at 2:30 PM PT. Management will hold one-on-one meetings with registered investors and potential partners to review the company's clinical development strategy, recent corporate achievements, and anticipated milestones.
The presentation will be delivered by Travis Whitfill, Chief Operating Officer, at the Hilton San Francisco Union Square (Yosemite C, Ballroom Level). Registration is available through the event website for accredited attendees.
Azitra (NYSE: AZTR) received NYSE American staff approval of its listing standards compliance plan under Section 1003(a)(ii).
Azitra previously received a notice for not meeting the $4.0 million minimum stockholders' equity requirement after reporting losses in three of the last four fiscal years. The company must regain compliance by April 1, 2027 or face potential delisting. Azitra will remain listed during monitoring and is exploring multiple funding avenues to achieve compliance.
Azitra (NYSE American: AZTR) entered a private placement with a single institutional investor to sell 4,687,500 shares of common stock (or pre-funded warrants in-lieu) together with warrants to purchase up to 4,687,500 shares.
The combined effective offering price per share plus warrant is $0.32, producing estimated gross proceeds of approximately $1.5 million before placement agent fees and expenses. The warrants have an exercise price of $0.32, will be exercisable upon shareholder approval, and expire five years after that approval. The Offering is expected to close on or about November 25, 2025. Maxim Group is sole placement agent. The company has agreed to file a resale registration statement with the SEC.